AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...

AbbVie previously acquired Stemcentrx in a $5.8bn deal in 2016 to gain access to an ADC targeting small cell lung cancer, but the drug ultimately failed to make a mark in clinical studies.

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average ...

AbbVie holds a strong portfolio of marketed ... and the $6 billion acquisition of Stemcentrx looks like poor judgment on a key cancer drug that looks less effective in late-stage clinical studies.

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...